Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marise R Heerma van Voss

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Biochimica Et Biophysica Acta. Reviews on Cancer|October 3, 2017
Targeting RNA helicases in cancer: The translation trapMarise R Heerma van Voss, Paul J van Diest, Venu Raman
The Lancet. Oncology|May 1, 2021
<sup>99m</sup>Tc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplastic syndrome in metastatic breast cancerArthur J A T Braat, Marise R Heerma van Voss, Rhodé M Bijlsma
Cancer Chemotherapy and Pharmacology|July 1, 2024
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patientsMarise R Heerma van Voss, Jessica Notohardjo, Joyce van Dodewaard-de Jong, et al.
Oncotarget|February 1, 2018
Role of DDX3 in the pathogenesis of inflammatory bowel diseaseSaritha Tantravedi, Farhad Vesuna, Paul T Winnard, et al.
Cellular Oncology (Dordrecht, Netherlands)|February 22, 2011
Expression of the stem cell marker ALDH1 in BRCA1 related breast cancerMarise R Heerma van Voss, Petra van der Groep, Joost Bart, et al.
Breast Cancer Research and Treatment|June 30, 2010
Expression of the stem cell marker ALDH1 in the normal breast of BRCA1 mutation carriersMarise R Heerma van Voss, Petra van der Groep, Joost Bart, et al.
BMC Cancer|April 20, 2010
Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controlsMarise R Heerma van Voss, Petra van der Groep, Jos Bart, et al.
British Journal of Clinical Pharmacology|June 29, 2025
Reply to: 'Methotrexate toxicity and glucarpidase: A call for dose optimization'Arjen Koppen, Maaike A Sikma, Frederike K Engels, et al.
Medical Oncology (Northwood, London, England)|February 1, 2017
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancerMarise R Heerma van Voss, Justin D Brilliant, Farhad Vesuna, et al.
British Journal of Clinical Pharmacology|March 12, 2025
Methotrexate toxicity and glucarpidase: A call for dose optimizationArjen Koppen, Maaike A Sikma, Frederike K Engels, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Biochimica Et Biophysica Acta. Reviews on Cancer|October 3, 2017
Targeting RNA helicases in cancer: The translation trapMarise R Heerma van Voss, Paul J van Diest, Venu Raman
The Lancet. Oncology|May 1, 2021
<sup>99m</sup>Tc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplastic syndrome in metastatic breast cancerArthur J A T Braat, Marise R Heerma van Voss, Rhodé M Bijlsma
Cancer Chemotherapy and Pharmacology|July 1, 2024
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patientsMarise R Heerma van Voss, Jessica Notohardjo, Joyce van Dodewaard-de Jong, et al.
Oncotarget|February 1, 2018
Role of DDX3 in the pathogenesis of inflammatory bowel diseaseSaritha Tantravedi, Farhad Vesuna, Paul T Winnard, et al.
Cellular Oncology (Dordrecht, Netherlands)|February 22, 2011
Expression of the stem cell marker ALDH1 in BRCA1 related breast cancerMarise R Heerma van Voss, Petra van der Groep, Joost Bart, et al.
Breast Cancer Research and Treatment|June 30, 2010
Expression of the stem cell marker ALDH1 in the normal breast of BRCA1 mutation carriersMarise R Heerma van Voss, Petra van der Groep, Joost Bart, et al.
BMC Cancer|April 20, 2010
Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controlsMarise R Heerma van Voss, Petra van der Groep, Jos Bart, et al.
British Journal of Clinical Pharmacology|June 29, 2025
Reply to: 'Methotrexate toxicity and glucarpidase: A call for dose optimization'Arjen Koppen, Maaike A Sikma, Frederike K Engels, et al.
Medical Oncology (Northwood, London, England)|February 1, 2017
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancerMarise R Heerma van Voss, Justin D Brilliant, Farhad Vesuna, et al.
British Journal of Clinical Pharmacology|March 12, 2025
Methotrexate toxicity and glucarpidase: A call for dose optimizationArjen Koppen, Maaike A Sikma, Frederike K Engels, et al.
Pageof 3